According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market value of HK$416 million, representing 9.23% of the company's shares. On July 28, ANTENGENE announced that China's National Medical Products Administration (NMPA) has approved Selinexor (in combination with bortezomib and dexamethasone (XVd)) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This represents a new indication for Selinexor.